TD Cowen Starts Helus Pharma (HELP) at Buy

TD Cowen analyst Ritu Baral initiates coverage on Helus Pharma (NASDAQ: HELP) with a Buy rating and a price target of $8.00.

The analyst comments "We are initiating on HELP with a Buy and $8 PT. We believe positive Ph2 adjunct MDD data for HLP003 (deuterated psilocin, COM IP to 2041) and precedent clinical data validating psilocybin-based tx in MDD/TRD de-risk the company's FDA-aligned Ph3 MDD program. The first Ph3 two-dose '003 MDD dataset is due in 4Q26, which could drive major upside. We model a 2028 launch and peak US sales of $1.3B."

For an analyst ratings summary and ratings history on Helus Pharma click here. For more ratings news on Helus Pharma click here.

Shares of Helus Pharma closed at $5.22 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Raymond James Starts SpyGlass Pharma (SGP) at Outperform
• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating